Top News

Amgen Completes Avidia Acquisition




Thousand Oaks-based Amgen has completed its acquisition of Mountain View-based Avidia, the firm said Tuesday afternoon. The previously announced acquisition was worth $290M. Avidia's lead product candidate is an inhibitor of interleukin 6, targeted at the treatment of inflammation and autoimmune diseases.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel